Trial
NCT06851104
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Guangxi Medical University
Collaborators
—
Condition
Hepatocellular Carcinoma (HCC)
Intervention
Cadonilimab (AK104)
Why stopped
The support from the relevant company was not obtained as planned
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-18